SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0600-6.3%Nov 10 3:45 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Khris Smith who wrote (12578)1/2/2014 8:09:34 AM
From: boomertree2  Read Replies (1) of 13111
 
No, I am not invested in ONCS. I try to follow other melanoma FDA trials since I am a heavily invested long in PVCT. The ONCS results are from a small patient pool, and the results appear to be materially inferior to PV-10. No patients received complete response. The ONCS partial response and stable disease results were also materially inferior to PV-10. However, it is difficult to compare one melanoma drug trial with another if the reported results don't indicate the stage of the melanoma cancer treated. PV-10 results were impressive for stage III melanoma, and less so with stage IV melanoma. The ONCS trial results don't indicate the stage of cancer treated.

There were 27 new FDA U.S. drug approvals in 2013, and many were breakthrough therapy approvals. The FDA cleared 12 fewer novel drugs in 2013 than the year before, though the rate was in line with historical averages.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News